Evidence map›Paper›PMID 28707161›Full record

Observational studySleep & breathing = Schlaf & Atmung2018

A weight-independent association between atypical antipsychotic medications and obstructive sleep apnea.

Habibolah Khazaie, Amir Sharafkhaneh, Sepideh Khazaie, Mohammad Rasoul Ghadami

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Sleep & breathing = Schlaf & Atmung, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05303935 (Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05303935 phase2completednot on this mapstarted 2022, after this paper: background citation

Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea

TypeinterventionalSponsorFlinders UniversityRan2022 to 2023Enrolled15ConditionsSleep Apnea, ObstructiveArmsQuetiapine 50 MG, Placebo
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Habibolah KhazaieSleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Amir SharafkhanehDepartment of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA.
Sepideh KhazaieSleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mohammad Rasoul GhadamiSleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. mr_ghadami@yahoo.com.
Kermanshah University of Medical Sciences · IRBaylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith increasing use of atypical antipsychotic (AAP) agents, the concern has been raised about the association between AAP agents and medical complications. Obstructive sleep apnea (OSA) is a common breathing disorder that adversely affects health and quality of life. Because the major risk factors for OSA are weight gain and obesity by altering the upper airway anatomy, an association between AAP and development of OSA is predictable. However, we hypothesized that AAP may promote OSA not only by weight gain but also because of its potential effects on upper airway muscle function. In the present study, we evaluated the possible association between AAP use and the severity of OSA.

methodsA sample of patients using AAP for treatment of paradoxical insomnia was evaluated before and at least 8 weeks after AAP use. Patients were divided based on type of AAP use to olanzapine, risperidone, and quetiapine groups. Patients used olanzapine (5-10 mg), risperidone (2-4 mg), or quetiapine (100-200 mg) 2 h before bedtime. Before and after treatment, respiratory variables were recorded using polysomnography. BMI, neck circumference (NC), and waist circumference (WC) were measured before and after treatment period.

resultsThere was no significant difference between pre- and post-treatment apnea index (0.2 ± 0.6 vs. 2.6 ± 4.3; p = 0.094) in olanzapine group. However, significant differences in hypopnea index (5.1 ± 5 vs. 30 ± 10.8; p < 0.0001) and AHI (5.3 ± 4.9 vs. 32.6 ± 9.6; p < 0.0001) were observed. Similar results were found in quetiapine and risperidone groups, except that in quetiapine group, apnea index was significantly increased after treatment period (0.7 ± 1.2 in pre-treatment vs. 3.1 ± 2.4 in post-treatment; p = 0.007). There were no significant changes in BMI, NC, and WC during treatment period in all three groups.

conclusionWhile AAP medications are known cause of weight gain as a main risk factor of OSA, our finding demonstrated a weight-independent association between AAP medications and worsening respiration during sleep.

Indexed as

AdultAntipsychotic AgentsFemaleHumansMaleMiddle AgedPolysomnographyQuality of LifeSleep Apnea, ObstructiveAntipsychotic AgentsAtypical antipsychoticObstructive sleep apneaPolysomnographyWeight gain

Identifiers

PMID28707161
OpenAlexW2734851190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.